Parenteral Anticoagulants: Special Considerations in Patients with Chronic Kidney Disease and Obesity

Erica E. Howe, Scott M. Wright, Regina Landis, Flora Kisuule, Addressing obesity in the hospitalized patient: a needs assessment. Southern Medical Journal. ,vol. 103, pp. 500- 504 ,(2010) , 10.1097/SMJ.0B013E3181DFD715

Roxana Mehran, Eugenia Nikolsky, Alexandra J. Lansky, Ajay J. Kirtane, Young-Hak Kim, Frederick Feit, Steven Manoukian, Jeffrey W. Moses, Ramin Ebrahimi, E. Magnus Ohman, Harvey D. White, Stuart J. Pocock, George D. Dangas, Gregg W. Stone, Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies JACC: Cardiovascular Interventions. ,vol. 2, pp. 748- 757 ,(2009) , 10.1016/J.JCIN.2009.05.018

_ _, Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. Journal of The National Comprehensive Cancer Network. ,vol. 6, pp. 716- ,(2008) , 10.6004/JNCCN.2008.0055

CA de Swart, B Nijmeyer, JM Roelofs, JJ Sixma, Kinetics of intravenously administered heparin in normal humans Blood. ,vol. 60, pp. 1251- 1258 ,(1982) , 10.1182/BLOOD.V60.6.1251.BLOODJOURNAL6061251

Isabelle Mahe, Isabelle Gouin-Thibault, Ludovic Drouet, Guy Simoneau, Heidi Di??Castillo, Virginie Siguret, Jean-Fran??ois Bergmann, Eric Pautas, Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs & Aging. ,vol. 24, pp. 63- 71 ,(2007) , 10.2165/00002512-200724010-00005

J. Y. V. Yee, S. B. Duffull, The effect of body weight on dalteparin pharmacokinetics. A preliminary study. European Journal of Clinical Pharmacology. ,vol. 56, pp. 293- 297 ,(2000) , 10.1007/S002280000141

M Laposata, R C Sosolik, E M Van Cott, D Green, S H Goodnight, T W Barrowcliffe, College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Archives of Pathology & Laboratory Medicine. ,vol. 122, pp. 799- 807 ,(1998)

B Adren, A Siegbahn, B Andren, E Swahn, R Nordlander, C Johansson, G Lindstrom, E Svensson, L Lundin, T Lundstrom, Å Hjalmarsson, E Karlsson, A Normark, K Wiklund, P Venge, L Wallentin, E Logander, G Almroth, F Landgren, H Saetre, E Enghoff, S Undeland, J Ohlsson, P Blomstrand, Low-molecular-weight heparin during instability in coronary artery disease The Lancet. ,vol. 347, pp. 561- ,(1996)

Susan I. O'Shea, Thomas L. Ortel, Eugene C. Kovalik, HEPARIN-INDUCED THROMBOCYTOPENIA IN DIALYSIS: Alternative Methods of Anticoagulation for Dialysis-dependent Patients with Heparin-induced Thrombocytopenia: ANTICOAGULATION IN HIT Seminars in Dialysis. ,vol. 16, pp. 61- 67 ,(2003) , 10.1046/J.1525-139X.2003.03014.X

William P. Yee, Linda L. Norton, Optimal weight base for a weight-based heparin dosing protocol American Journal of Health-system Pharmacy. ,vol. 55, pp. 159- 162 ,(1998) , 10.1093/AJHP/55.2.159